Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ACR-368 in high-grade endometrial adenocarcinoma
2025-524542-10-00Phase 2Authorised
- Sponsor
- Acrivon Therapeutics, Inc.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of prexasertib in endometrial cancer (EC) and endometrial adenocarcinoma, sponsored by Acrivon Therapeutics, Inc. Primary endpoint: Confirmed objective response rate. Planned start Apr 2026; status: authorised.
02
Drugs
prexasertib
03
Conditions
endometrial cancer (EC)endometrial adenocarcinoma
Beyond the preview
Go deeper on 2025-524542-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524542-10-00.